SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Koopman Miriam)
 

Sökning: WFRF:(Koopman Miriam) > Comparing Circulati...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003648naa a2200337 4500
001oai:DiVA.org:uu-422997
003SwePub
008201019s2020 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4229972 URI
024a https://doi.org/10.1158/1078-0432.CCR-19-25702 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Netterberg, Idau Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)idane961
2451 0a Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival :b A Quantitative Modeling Framework
264 1b AMER ASSOC CANCER RESEARCH,c 2020
338 a print2 rdacarrier
520 a Purpose: Quantitative relationships between treatment-induced changes in tumor size and circulating tumor cell (CTC) counts, and their links to overall survival (OS), are lacking. We present a population modeling framework identifying and quantifying such relationships, based on longitudinal data collected in patients with metastatic colorectal cancer (mCRC) to evaluate the value of tumor size and CTC counts as predictors of OS. Experimental Design: A pharmacometric approach (i.e., population pharmacodynamic modeling) was used to characterize the changes in tumor size and CTC count and evaluate them as predictors of OS in 451 patients with mCRC treated with chemotherapy and targeted therapy in a prospectively randomized phase III study (CAIRO2). Results: A tumor size model of tumor quiescence and drug resistance was used to characterize the tumor size time-course, and was, in addition to the total normalized dose (i.e., of all administered drugs) in a given cycle, related to the CTC counts through a negative binomial model (CTC model). Tumor size changes did not contribute additional predictive value when themean CTC count was a predictor of OS. Treatment reduced the typical mean count from 1.43 to 0.477 (HR = 3.94). The modeling framework was applied to explore whether dose modifications (increased and reduced) would result in a CTC count below 1/7.5 mL after 1 to 2 weeks of treatment. Conclusions: Time-varying CTC counts can be useful for early predicting OS in patients with mCRC, and may therefore have potential for model-based treatment individualization. Although tumor size was connected to CTC, its link to OS was weaker.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
700a Karlsson, Matsu Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)matskarl
700a Terstappen, Leon W. M. M.u Univ Twente, Fac Sci & Technol, Dept Med Cell BioPhys, Enschede, Netherlands.4 aut
700a Koopman, Miriamu Univ Utrecht, Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands.4 aut
700a Punt, Cornelis J. A.u Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Med Oncol, Amsterdam, Netherlands.4 aut
700a Friberg, Lenau Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)lenasimo
710a Uppsala universitetb Institutionen för farmaceutisk biovetenskap4 org
773t Clinical Cancer Researchd : AMER ASSOC CANCER RESEARCHg 26:18, s. 4892-4900q 26:18<4892-4900x 1078-0432x 1557-3265
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-422997
8564 8u https://doi.org/10.1158/1078-0432.CCR-19-2570

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy